Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.
Clin Exp Metastasis
; 40(5): 423-429, 2023 10.
Article
em En
| MEDLINE
| ID: mdl-37584783
ABSTRACT
The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Pequenas Células do Pulmão
/
Neoplasias Pulmonares
Tipo de estudo:
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Exp Metastasis
Ano de publicação:
2023
Tipo de documento:
Article